- Raw materials
- Antifungals
- Saccharomyces cerevisiae
Saccharomyces cerevisiae API Manufacturers & Suppliers
0 verified results
All Saccharomyces cerevisiae data. Full access. Full negotiation power
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Saccharomyces cerevisiae | CAS No: 68876-77-7 | GMP-certified suppliers
A medication that serves as a non-standardized fungal allergenic extract for assessing cell-mediated immunity, histamine release, and IgG production in allergy diagnostics.
Therapeutic categories
Product Snapshot
- Saccharomyces cerevisiae is available in multiple formulation types including injectable solutions, oral tablets and capsules, topical gels and ointments, powders, and suppositories
- Its primary therapeutic uses span various administration routes such as intradermal, subcutaneous, oral, rectal, and topical applications
- The product is approved for use in the US market
Clinical Overview
Clinically, Saccharomyces cerevisiae is employed mainly in allergenic testing. It serves as a non-standardized fungal allergenic extract used to assess cell-mediated immunity responses, as well as increased histamine release and IgG antibody production in patients suspected of allergic sensitivities. Despite being approved for use in this diagnostic capacity, no specific therapeutic indications or standardized pharmacodynamic profiles are established for this product.
The exact mechanism of action involved in the allergic response triggered by Saccharomyces cerevisiae extracts remains incompletely characterized. Its role centers on the stimulation of immune effector cells, contributing to the release of histamine and the production of IgG antibodies, which are markers of hypersensitivity.
Pharmacokinetic parameters such as absorption, distribution, metabolism, and excretion are not detailed due to its nature as an allergenic extract rather than a conventional systemic drug. Safety considerations focus predominantly on its potential to induce allergic reactions, which requires careful handling and appropriate dosing during diagnostic procedures to mitigate adverse effects.
Notable applications of Saccharomyces cerevisiae allergenic extracts are primarily within immunological laboratories and clinical allergy assessments, supporting differential diagnosis of fungal-related hypersensitivity.
Regarding API procurement, quality control is critical given the variability inherent in biological extracts. Suppliers must ensure batch-to-batch consistency, verified identity, and purity according to regulatory guidelines for allergenic products. Proper sourcing includes validation of fungal strain origin and standardized procedures for extraction to maintain immunological activity and safety profiles.
Identification & chemistry
| Generic name | Saccharomyces cerevisiae |
|---|---|
| Molecule type | Biotech |
| CAS | 68876-77-7 |
| UNII | 978D8U419H |
| DrugBank ID | DB10447 |
Formulation & handling
- Saccharomyces cerevisiae is available in multiple routes including injectable (intradermal, subcutaneous), oral, topical, rectal, and parenteral forms, indicating diverse formulations.
- As a biotech product, handling requires adherence to sterility and stability conditions suitable for biologics, with injectable forms necessitating careful cold chain management.
- Oral and topical formulations may exhibit variability in bioavailability and stability, requiring formulation optimization for protection against gastrointestinal conditions and skin barrier interaction.
Regulatory status
| Lifecycle | The active pharmaceutical ingredient is marketed primarily in the US, with key patents having expired, leading to the availability of generic formulations and an established market presence. |
|---|
| Markets | US |
|---|
Supply Chain
| Supply chain summary | The manufacturing landscape for Saccharomyces cerevisiae involves several originator companies supplying various branded products predominantly in the US market. Branded formulations such as A Mold Mixture, Bakers Yeast, and Brewers Yeast demonstrate focused regional availability without significant presence indicated in the EU or other territories. Patent expirations in this space suggest existing generic competition, reflecting a mature market with established supply chains. |
|---|
Saccharomyces cerevisiae is a type of Antifungals
Antifungals are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) designed to combat fungal infections. These medications are developed to target and eliminate fungi, including yeasts and molds, which can cause a range of diseases in humans and animals.
Antifungals work by interfering with specific components or processes essential for fungal growth and reproduction. They may inhibit the synthesis of fungal cell walls or disrupt the production of ergosterol, a crucial component of fungal cell membranes. By targeting these key mechanisms, antifungal APIs effectively hinder the growth and spread of fungal infections.
The diversity within the antifungal category is reflected in the various classes of antifungal APIs available. Azoles, polyenes, echinocandins, and allylamines are common classes of antifungals. Each class exhibits unique mechanisms of action and targets specific types of fungi. This diversity enables healthcare professionals to tailor treatment plans to the specific fungal infection, optimizing therapeutic outcomes.
Antifungal APIs find application in various pharmaceutical formulations, including oral medications, topical creams, ointments, and intravenous solutions. They are crucial for the treatment of common fungal infections like athlete's foot, ringworm, vaginal yeast infections, and oral thrush. Additionally, antifungals play a crucial role in managing serious systemic fungal infections that can pose significant health risks, especially in immunocompromised individuals.
Overall, antifungal APIs are indispensable tools in the fight against fungal infections, offering effective treatment options and improving the quality of life for patients suffering from these conditions. With ongoing research and development, the antifungal category continues to evolve, providing innovative solutions to combat the ever-changing landscape of fungal pathogens.
